Company profile
Neurosterix Pharma Sàrl
Privately held: no public share price (Private Swiss biotech, spun off from Addex Therapeutics; launched 2024 with $63M Series A. Lead program NTX-253/NTX110253 (M4 PAM) for schizophrenia. No evidence of a public listing. Not found in roster. Sources: https://clinicaltrials.gov/study/NCT07344948 ; https://www.biospace.com/neurosterix-launches-with-63m-to-advance-allosteric-modulator-therapeutics-for-neurological-disorders Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | Muscarinic M4 receptorSmall molecule | Schizophrenia |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.